Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.

Shani Paluch-ShimonPatrick NevenJens HuoberIrfan CicinMatthew P GoetzChikako ShimizuChiun-Sheng HuangHans Joachim LueckJane BeithEriko TokunagaJessica Reyes ContrerasRosane Oliveira de Sant'AnaRan WeiAshwin ShahirSarah C NabingerTammy ForresterStephen R D JohnstonNadia Harbeck

Published in: Therapeutic advances in medical oncology (2023)

ET alone regardless of menopausal status and first ET, with a numerically greater benefit in the premenopausal compared to the postmenopausal population. Safety data in premenopausal patients are consistent with the overall safety profile of abemaciclib.

Keyphrases

early breast cancer
end stage renal disease
postmenopausal women
chronic kidney disease
ejection fraction
newly diagnosed
early stage
prognostic factors
lymph node
electronic health record
patient reported outcomes
big data
body composition
deep learning
patient reported
replacement therapy
smoking cessation